Rationale and design of the open-label, prospective, randomized study of the efficacy of intravenous versus oral iron deficiency therapy in improving left ventricular systolic function in patients with myocardial infarction (OPERA-MI)

Aim. Iron has a protective effect on cardiomyocytes during hypoxia, while iron deficiency (ID) directly affects its function, disrupting mitochondrial respiration, reducing their contractility and relaxation. Some studies have shown that ID is a predictor of adverse outcomes  in patients with acute...

Full description

Saved in:
Bibliographic Details
Main Authors: D R Khastieva, M I Malkova, E B Zakirova, I I Zakirova, I H Valeeva, N R Khasanov
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC 2022-06-01
Series:Российский кардиологический журнал
Subjects:
Online Access:https://russjcardiol.elpub.ru/jour/article/view/4961
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850030975022530560
author D R Khastieva
M I Malkova
E B Zakirova
I I Zakirova
I H Valeeva
N R Khasanov
author_facet D R Khastieva
M I Malkova
E B Zakirova
I I Zakirova
I H Valeeva
N R Khasanov
author_sort D R Khastieva
collection DOAJ
description Aim. Iron has a protective effect on cardiomyocytes during hypoxia, while iron deficiency (ID) directly affects its function, disrupting mitochondrial respiration, reducing their contractility and relaxation. Some studies have shown that ID is a predictor of adverse outcomes  in patients with acute coronary syndrome (ACS).  However, the impact of ID and its treatment, quality of life and prognosis of patients with ID and myocardial infarction (MI) has not been fully established. The study aim is to determine the effectiveness of intravenous ferric carboxymaltose  (FCM) compared  with oral iron (ferrous sulfate) in relation to left ventricular (LV) systolic function, assessed by echocardiography.Material and methods. This open-label, prospective, randomized study includes 360 patients  with or without ID who were  hospitalized  with acute  myocardial infarction (MI).  Patients with ID will be randomized (1:1) to intravenous FCM and oral ferrous sulfate therapy. Treatment in groups will be started at the time of hospitalization. Patients without ID will form the control group.  The follow-up period for patients will be 1 year. The primary endpoint was a reduction  in LV wall motion score  index (WMSI) in the FCM group compared  to the ferrous sulfate group. The key secondary endpoint is a composite endpoint of cardiovascular death, non-fatal MI and stroke, and hospitalization for decompensated heart failure.Conclusion. The OPERA-MI study will determine the effect  of ID treatment with intravenous FCM compared  with oral ferrous sulfate on WMSI, which reflects LV systolic function.
format Article
id doaj-art-5578015ef86a4d1591ebb3630eb5081e
institution DOAJ
issn 1560-4071
2618-7620
language Russian
publishDate 2022-06-01
publisher «FIRMA «SILICEA» LLC
record_format Article
series Российский кардиологический журнал
spelling doaj-art-5578015ef86a4d1591ebb3630eb5081e2025-08-20T02:59:06Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202022-06-01272S10.15829/1560-4071-2022-49613575Rationale and design of the open-label, prospective, randomized study of the efficacy of intravenous versus oral iron deficiency therapy in improving left ventricular systolic function in patients with myocardial infarction (OPERA-MI)D R Khastieva0M I Malkova1E B Zakirova2I I Zakirova3I H Valeeva4N R Khasanov5Kazan State Medical UniversityKazan State Medical University; City Clinical Hospital № 7City Clinical Hospital № 7City Clinical Hospital № 7Kazan State Medical UniversityKazan State Medical UniversityAim. Iron has a protective effect on cardiomyocytes during hypoxia, while iron deficiency (ID) directly affects its function, disrupting mitochondrial respiration, reducing their contractility and relaxation. Some studies have shown that ID is a predictor of adverse outcomes  in patients with acute coronary syndrome (ACS).  However, the impact of ID and its treatment, quality of life and prognosis of patients with ID and myocardial infarction (MI) has not been fully established. The study aim is to determine the effectiveness of intravenous ferric carboxymaltose  (FCM) compared  with oral iron (ferrous sulfate) in relation to left ventricular (LV) systolic function, assessed by echocardiography.Material and methods. This open-label, prospective, randomized study includes 360 patients  with or without ID who were  hospitalized  with acute  myocardial infarction (MI).  Patients with ID will be randomized (1:1) to intravenous FCM and oral ferrous sulfate therapy. Treatment in groups will be started at the time of hospitalization. Patients without ID will form the control group.  The follow-up period for patients will be 1 year. The primary endpoint was a reduction  in LV wall motion score  index (WMSI) in the FCM group compared  to the ferrous sulfate group. The key secondary endpoint is a composite endpoint of cardiovascular death, non-fatal MI and stroke, and hospitalization for decompensated heart failure.Conclusion. The OPERA-MI study will determine the effect  of ID treatment with intravenous FCM compared  with oral ferrous sulfate on WMSI, which reflects LV systolic function.https://russjcardiol.elpub.ru/jour/article/view/4961iron deficiencymyocardial infarctionferric carboxymaltoseleft ventricular systolic functionwall motion score index
spellingShingle D R Khastieva
M I Malkova
E B Zakirova
I I Zakirova
I H Valeeva
N R Khasanov
Rationale and design of the open-label, prospective, randomized study of the efficacy of intravenous versus oral iron deficiency therapy in improving left ventricular systolic function in patients with myocardial infarction (OPERA-MI)
Российский кардиологический журнал
iron deficiency
myocardial infarction
ferric carboxymaltose
left ventricular systolic function
wall motion score index
title Rationale and design of the open-label, prospective, randomized study of the efficacy of intravenous versus oral iron deficiency therapy in improving left ventricular systolic function in patients with myocardial infarction (OPERA-MI)
title_full Rationale and design of the open-label, prospective, randomized study of the efficacy of intravenous versus oral iron deficiency therapy in improving left ventricular systolic function in patients with myocardial infarction (OPERA-MI)
title_fullStr Rationale and design of the open-label, prospective, randomized study of the efficacy of intravenous versus oral iron deficiency therapy in improving left ventricular systolic function in patients with myocardial infarction (OPERA-MI)
title_full_unstemmed Rationale and design of the open-label, prospective, randomized study of the efficacy of intravenous versus oral iron deficiency therapy in improving left ventricular systolic function in patients with myocardial infarction (OPERA-MI)
title_short Rationale and design of the open-label, prospective, randomized study of the efficacy of intravenous versus oral iron deficiency therapy in improving left ventricular systolic function in patients with myocardial infarction (OPERA-MI)
title_sort rationale and design of the open label prospective randomized study of the efficacy of intravenous versus oral iron deficiency therapy in improving left ventricular systolic function in patients with myocardial infarction opera mi
topic iron deficiency
myocardial infarction
ferric carboxymaltose
left ventricular systolic function
wall motion score index
url https://russjcardiol.elpub.ru/jour/article/view/4961
work_keys_str_mv AT drkhastieva rationaleanddesignoftheopenlabelprospectiverandomizedstudyoftheefficacyofintravenousversusoralirondeficiencytherapyinimprovingleftventricularsystolicfunctioninpatientswithmyocardialinfarctionoperami
AT mimalkova rationaleanddesignoftheopenlabelprospectiverandomizedstudyoftheefficacyofintravenousversusoralirondeficiencytherapyinimprovingleftventricularsystolicfunctioninpatientswithmyocardialinfarctionoperami
AT ebzakirova rationaleanddesignoftheopenlabelprospectiverandomizedstudyoftheefficacyofintravenousversusoralirondeficiencytherapyinimprovingleftventricularsystolicfunctioninpatientswithmyocardialinfarctionoperami
AT iizakirova rationaleanddesignoftheopenlabelprospectiverandomizedstudyoftheefficacyofintravenousversusoralirondeficiencytherapyinimprovingleftventricularsystolicfunctioninpatientswithmyocardialinfarctionoperami
AT ihvaleeva rationaleanddesignoftheopenlabelprospectiverandomizedstudyoftheefficacyofintravenousversusoralirondeficiencytherapyinimprovingleftventricularsystolicfunctioninpatientswithmyocardialinfarctionoperami
AT nrkhasanov rationaleanddesignoftheopenlabelprospectiverandomizedstudyoftheefficacyofintravenousversusoralirondeficiencytherapyinimprovingleftventricularsystolicfunctioninpatientswithmyocardialinfarctionoperami